

Data Sheet

<b>NAME:</b>	vT183
<b>REPOSITORY REFERENCE:</b>	ARP2124
<b>PROVIDED:</b>	1 vial cell-free virus (NYCBH), $1.1 \times 10^{10}$ pfu/ml.
<b>DESCRIPTION:</b>	The HIV-1 <sub>92UG037.1</sub> <i>env</i> gene was modified to introduce silent mutations to remove two internal T <sub>5</sub> NT sequences encoding vaccinia virus early transcription termination sequences. A plasmid containing the vaccinia K1L gene and the modified <i>env</i> gene under control of the vaccinia 40K promoter was transfected into RK <sub>13</sub> cells infected with vAbT33, a K1L <sup>-</sup> , M2L <sup>-</sup> , LacZ <sup>+</sup> derivative of the NYCBH strain that cannot grow on RK <sub>13</sub> cells due to the absence of the K1L host range gene. The resultant recombinant, vT183, was isolated and purified in RK <sub>13</sub> cells.
<b>CHARACTERISTICS:</b>	Cells infected with vT173 express the HIV-1 <sub>92UG037.1</sub> <i>env</i> gene (subtype A).
<b>STORAGE:</b>	-70°C.
<b>SOURCE:</b>	Therion Biologics Corporation, in collaboration with Dr. Feng Gao and Dr. Beatrice Hahn. Viruses expanded by Quality Biological, Inc. (Courtesy of NIH AIDS Research and Reference Reagent Program)

**REFERENCES:**

Gao F, et al. *J Virol* **70**:7013, 1996.

**ACKNOWLEDGEMENTS:**

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)

**NOTE:**

Limited to 1 aliquot per laboratory. Available only for non-commercial use. Requests from commercial institutions should be directed to Dr. Gail Mazzara, Vice President, R&D, Therion Biologics Corp., 76 Rogers St., Cambridge, MA 02142.